The SERENADA Study for people with agitation and aggression due to Alzheimer’s Desease Dementia
Now enrolling in the U.S, Canada and UK – Find Study Site here
Help us to improve life in Alzheimer’s disease.
A study designed for patients — and the people who care for them.
Caring for someone with Alzheimer’s Disease Dementia can be physically and emotionally demanding—especially when symptoms such as agitation and aggression affect daily life. The SERENADA study is a clinical research study exploring investigational treatment options for these challenging symptoms.
By taking part, participants receive regular medical assessments and close health monitoring throughout the study. Caregivers are supported with clear guidance, structured study visits, and direct access to the study team. Participation also offers the opportunity to contribute to research that may help improve care options for patients and families in the future.
Important Answers
The SERENADA study is a clinical research study evaluating two investigational drugs, EXV-802 and EXV-801, for people with agitation and aggression due to Alzheimer’s Disease Dementia. The study compares these investigational drugs with a placebo.
A clinical research study is conducted to learn more about investigational treatments before they are approved and made available to patients. Participation is voluntary, and people who take part help advance medical research.
Current treatment options for agitation and aggression in Alzheimer’s Disease Dementia are limited and often associated with significant side effects. This study aims to explore safer, non-antipsychotic treatment options.
To be eligible, a person must: >>> Be between 55 and 90 years of age >>> Have a diagnosis of agitation and aggression due to Alzheimer’s Disease Dementia >>> Have a caregiver or support person who can attend study visits and help with medication
Additional criteria apply and will be reviewed by the study doctor during screening.
Participation lasts up to approximately 14 weeks and includes: >>> A screening period (up to 4 weeks) >>> A treatment period (6 weeks) >>> A follow-up period (4 weeks)
There is no cost to take part. Study medications, tests, and procedures related to the study are provided at no charge. Information about possible reimbursement for study-related expenses will be provided by the study team.
Important Answers for caregivers
Because participants have Alzheimer’s Disease Dementia, a caregiver is essential to help ensure study medication is taken correctly, attend clinic visits, and accurately report changes in behavior, health, or daily functioning.
Caregivers will be asked to: >>> Attend study visits with the participant >>> Help administer the study medication twice daily >>> Record medication intake in a diary >>> Observe and report changes in behavior, mood, or health >>> Communicate with the study team as needed
The study lasts up to approximately 14 weeks and includes at least 6 in-person clinic visits. Visit length may vary depending on scheduled assessments.
Where do the SERENADA studies take place?
Caring for someone with Alzheimer’s can feel overwhelming. Talk with a local study team.
Reaching out to a nearby study site gives caregivers the chance to speak with a supportive, experienced research team who understands these challenges. They can listen to your concerns, explain what participation would look like in practical terms, and help you understand what support is available throughout the study.
There is no obligation to take part. It is simply an opportunity to ask questions, gather information, and take the time you need to decide what feels right for you and the person you care for.
